The trusted source for
healthcare information and
The Global Alliance for TB Drug Development has begun going through a stack of letters from researchers around the world who are interested in making a formal application for alliance funding.
About 90 letters offering a brief description of proposed projects and research have arrived so far, says Rick O’Brien, chairman of the alliance’s Scientific Advisory Committee. Those letters, responses to notices the alliance has placed in journals and elsewhere, "are about the number we’d been expecting to get."
Now, O’Brien’s committee must select the most promising projects and ask for full proposals. Final decisions on who gets to submit proposals should be made this month, he says.
The Global Alliance is a consortium of public and private stakeholders that was formed to spur the development of novel anti-TB drugs. Under the prevailing market-driven system, only a single new anti-TB drug, rifapentine, has been approved for TB treatment in the past 20 years.